- New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced
- Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat, in a gold-standard animal study
- Reduced COVID-19 replication by up to 96%, study performed by Public Health England (PHE) scientists
- Mode of action complementary to COVID-19 vaccines, with easy nasal administration, delivered once or twice a week
- Potential to be used to prevent infection in at-risk populations, including healthcare workers and the elderly
- Ready to progress to human clinical trials within four months
- Company has raised AU$11.7m and is seeking additional investment
Source: Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
